Korro Bio financials
$9.56+0.53%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $6.4M | $2.3M | $0.00 |
| Gross profit | $6.4M | $2.3M | $0.00 |
| Gross margin | 100.0% | 100.0% | — |
| Operating income | -$121.9M | -$91.9M | -$84.5M |
| Net income | -$117.3M | -$83.6M | -$81.2M |
| Net margin | −1834.5% | −3680.4% | — |
| Diluted EPS | $-12.48 | $-9.37 | $-53.08 |
| EBITDA | -$83.1M | -$88.3M | -$80.9M |
| Operating cash flow | -$78.6M | -$60.1M | -$67.3M |
| Free cash flow | -$79.1M | -$78.0M | -$75.1M |
| Diluted shares | 9.4M | 8.9M | 1.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $21.8M | $55.6M | $166.2M |
| Short-term investments | $53.3M | $70.5M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 |
| Total assets | $113.5M | $226.2M | $221.7M |
| Total liabilities | $62.1M | $65.8M | $51.8M |
| Shareholders' equity | $51.4M | $160.4M | $169.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology